Frank Garred

Articles by Frank Garred

Frank Garred, 77, completed TAR-200 treatment for recurrent bladder cancer, describing it as manageable with minimal side effects compared with BCG.

Positive Experience With TAR-200 for Recurrent Bladder Cancer

September 30th 2025

Frank Garred, 77, completed TAR-200 treatment for recurrent bladder cancer, describing it as manageable with minimal side effects compared with BCG.

Latest Updated Articles

Trending on CURE

New Strategy May Prevent Breast Cancer Relapse

Combination Therapies May Improve Survival in EGFR+ Lung Cancer

Why Multidisciplinary Care is Crucial in Prostate Cancer

Mytesi Seeks FDA Orphan Drug Designation in Breast Cancer Diarrhea

I No Longer Think About Cancer Every Day

© 2025 MJH Life Sciences^®

All rights reserved.